Skip to main content
Journal cover image

Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin': reply from the authors.

Publication ,  Journal Article
Penny, CL; Quow, K; Rundle, CW; Al-Rohil, RN; Cardones, AR; Kheterpal, MK; Fresco, AI
Published in: Br J Dermatol
August 2022

Duke Scholars

Published In

Br J Dermatol

DOI

EISSN

1365-2133

Publication Date

August 2022

Volume

187

Issue

2

Start / End Page

275 / 276

Location

England

Related Subject Headings

  • Skin Diseases
  • Immunoconjugates
  • Humans
  • Fluorescent Antibody Technique, Direct
  • Dermatology & Venereal Diseases
  • Antibodies, Monoclonal
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Penny, C. L., Quow, K., Rundle, C. W., Al-Rohil, R. N., Cardones, A. R., Kheterpal, M. K., & Fresco, A. I. (2022). Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin': reply from the authors. Br J Dermatol, 187(2), 275–276. https://doi.org/10.1111/bjd.21239
Penny, Caitlin L., Krystina Quow, Chandler W. Rundle, Rami N. Al-Rohil, Adela R. Cardones, Meenal K. Kheterpal, and Amber I. Fresco. “Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin': reply from the authors.Br J Dermatol 187, no. 2 (August 2022): 275–76. https://doi.org/10.1111/bjd.21239.
Penny CL, Quow K, Rundle CW, Al-Rohil RN, Cardones AR, Kheterpal MK, et al. Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin': reply from the authors. Br J Dermatol. 2022 Aug;187(2):275–6.
Penny, Caitlin L., et al. “Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin': reply from the authors.Br J Dermatol, vol. 187, no. 2, Aug. 2022, pp. 275–76. Pubmed, doi:10.1111/bjd.21239.
Penny CL, Quow K, Rundle CW, Al-Rohil RN, Cardones AR, Kheterpal MK, Fresco AI. Response to 'Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin': reply from the authors. Br J Dermatol. 2022 Aug;187(2):275–276.
Journal cover image

Published In

Br J Dermatol

DOI

EISSN

1365-2133

Publication Date

August 2022

Volume

187

Issue

2

Start / End Page

275 / 276

Location

England

Related Subject Headings

  • Skin Diseases
  • Immunoconjugates
  • Humans
  • Fluorescent Antibody Technique, Direct
  • Dermatology & Venereal Diseases
  • Antibodies, Monoclonal
  • 3202 Clinical sciences
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences